A

Avalyn Pharma

Inhaled therapies for rare respiratory diseases

Director – Clinical Development Research Scientist

Clinical Research OperationsConfirmed live in the last 24 hours
Full-timeRemote in USA$220k - $242k

About the Job

Requirements

  • An advanced clinical or scientific degree, such as DNP, APRN, MD, PhD, or equivalent, with significant clinical research, clinical development, or relevant therapeutic-area experience.
  • 7–10+ years of experience in clinical research, clinical development, drug development, or a related field, including meaningful sponsor-side experience.
  • Deep expertise in idiopathic pulmonary fibrosis, interstitial lung disease, or pulmonary medicine, with a strong understanding of the treatment landscape and unmet patient needs.
  • Demonstrated experience leading or contributing to Phase 2 and/or Phase 3 clinical trials, including protocol development, clinical trial strategy, safety monitoring, and risk mitigation.
  • Ability to interpret clinical safety and efficacy data and translate findings into evidence-based, program-level development decisions.
  • Experience contributing to clinical development strategy across multiple studies and/or development stages, connecting study-level decisions to broader program, portfolio, and product objectives.
  • Working knowledge of ICH-GCP and global regulatory requirements, with experience supporting health authority interactions and clinical/regulatory documentation.
  • Experience managing, mentoring, and developing clinical development professionals.
  • Ability to engage effectively with investigators, key opinion leaders, regulatory agencies, senior leadership, and cross-functional stakeholders.
  • Ability to evaluate benefit-risk considerations, make clear recommendations, and influence decisions across the organization.
  • Ability to balance strategic responsibilities with hands-on clinical development activities in a fast-paced environment.
  • Willingness and ability to travel up to 25% domestically and internationally for investigator meetings, advisory boards, site visits, scientific conferences, and other clinical development activities.

Responsibilities

  • Provide clinical and scientific expertise for Avalyn idiopathic pulmonary fibrosis/interstitial lung disease programs and contribute to broader portfolio and development strategy.
  • Develop and refine clinical trial strategies, including study sequencing, objectives, endpoints, patient populations, and overall program design.
  • Lead cross-functional development discussions and evaluate program risks, opportunities, and development alternatives to inform study design, sequencing, and resource priorities.
  • Provide strategic clinical input into development plans, target product profiles, and key program milestones.
  • Lead protocol development, including study objectives, endpoints, eligibility criteria, safety monitoring, and risk mitigation.
  • Provide clinical and scientific leadership across multiple studies, ensuring consistency and scientific rigor across the development program.
  • Contribute to statistical analysis plan assumptions and assess the clinical relevance and interpretability of statistical approaches.
  • Provide clinical oversight into study feasibility, investigator and site selection, protocol amendments, and study-level development decisions.
  • Partner with Clinical Operations and contract research organizations to support effective study execution while maintaining scientific integrity and patient safety.
  • Serve as an idiopathic pulmonary fibrosis/interstitial lung disease disease-area expert and provide medical guidance across assigned programs.
  • Provide medical oversight to study teams and Medical Monitors, including assessment of patient safety, clinical risk, and disease-specific considerations.
  • Lead clinical data reviews and interpret emerging safety and efficacy data across studies.
  • Identify cross-study trends and translate findings into clinical and development recommendations.
  • Partner with Biostatistics, Data Management, Pharmacovigilance, and Translational Science on data review, interpretation, and benefit-risk assessment.
  • Provide clinical and scientific leadership in the development and review of protocols, Investigator Brochures, Clinical Study Reports, briefing documents, and regulatory submissions.
  • Lead Clinical Study Report authoring and ensure appropriate clinical interpretation of study findings.
  • Support FDA and other health authority interactions, including end-of-Phase 2 meetings and responses to regulatory questions.
  • Contribute to regulatory strategy and translate clinical data and program strategy into clear, scientifically rigorous regulatory narratives.
  • Serve as a senior clinical leader on multidisciplinary development teams and provide clear recommendations to senior leadership.
  • Build strong relationships with investigators, key opinion leaders, external experts, contract research organizations, and other external partners.
  • Provide clinical and scientific leadership at investigator meetings, advisory boards, and other external forums.
  • Support identification and engagement of clinical experts and investigators to inform program strategy and trial design.
  • Contribute to publication strategy and external dissemination of clinical development data.
  • Lead or support abstracts, posters, manuscripts, presentations, and scientific publications.
  • Present clinical development strategy and emerging data at investigator meetings, advisory boards, scientific congresses, and other external forums.
  • Maintain awareness of evolving idiopathic pulmonary fibrosis/interstitial lung disease literature, treatment paradigms, competitive developments, and standards of care.

About the Company

Avalyn Pharma

Inhaled therapies for rare respiratory diseases

Avalyn Pharma develops inhaled therapies for rare respiratory diseases. Its lead program, AP01, is an inhaled formulation of pirfenidone in Phase 2b trials designed to treat pulmonary fibrosis and other interstitial lung diseases. The inhaled approach aims to deliver therapy directly to the lungs, potentially improving efficacy and convenience while reducing systemic exposure. The company differentiates itself by focusing on inhaled versions of already approved medications to target lung diseases more precisely, addressing conditions with limited treatment options. Its goal is to advance clinical development and move toward commercialization of these inhaled therapies, ultimately improving patient outcomes and quality of life for people with rare lung diseases.

Company size
51-200
Company stage
IPO
Headquarters
Boston, MA
Founded
2011

Recently Posted Jobs

Explore more opportunities at Avalyn Pharma

See more jobs